Astria Therapeutics in the spotlight (part III)

>150% gains since last month but Boutique Biotech still holding position

Astria Therapeutics (ATXS) is up over 150% since we first bought a position in early August under $4/share (see our previous post here). Boutique Biotech will not be selling its position yet (rationale provided below). The Company initiated the Phase 1 program for their STAR-0215 candidate in healthy volunteers. Phase 1 data is expected towards the end…